July 17, 2009 -
July 17, 2009 Vicriviroc Trial in Treatment Newbies Gets OK to Continue A clinical trial investigating the entry inhibitor vicriviroc in people new to HIV treatment has gotten ... 15 by the drug s developer, Schering-Plough. Vicriviroc is a CCR5 inhibitor, very similar to Selzentry ... treatment newbies and is comparing a regimen of vicriviroc plus Norvir (ritonavir)-boosted Reyataz (atazanavir) with a ...
http://www.aidsmeds.com/articles/1667_16931.shtml
April 15, 2008 -
April 15, 2008 Vicriviroc Trial Enrolling Treatment First-Timers Schering-Plough Corporation ... study of its experimental CCR5-blocking entry inhibitor vicriviroc for people starting HIV treatment for the first ... positive people new to antiretroviral (ARV) treatment, the vicriviroc regimen being tested in this study does not ... will be allotted to receive either 30 mg vicriviroc once daily combined with Norvir (ritonavir)-boosted Reyataz ... Norvir-boosted Reyataz. Another phase II study of vicriviroc, which is similar to Pfizer s approved ...
http://www.aidsmeds.com/articles/hiv_aids_vicriviroc_1667_14434.shtml
February 26, 2008 -
... new drug that’s not yet approved called Vicriviroc, from Schering; it’s an entry inhibitor, a ... a medication like a CCR5 antagonist, like a Vicriviroc, are probably going to be on a boosted ... not only the protease inhibitor but also the Vicriviroc. Today we saw forty-eight week data—which ...
http://www.aidsmeds.com/articles/hiv_aids_treatment_2151_14104.shtml
September 26, 2007 -
David Evans -
... Selzentry is one such compound, and Schering’s vicriviroc is still being tested. GSK’s compound fizzled ... tropism switches have been documented in Selzentry and vicriviroc clinical trials, they haven’t been linked to ... treatment-experienced. Earlier this month, Schering announced that vicriviroc has entered Phase III clinical trials. Unlike Selzentry, which must be taken twice a day, vicriviroc is being studied as a once-a-day ...
http://www.aidsmeds.com/articles/tropism_CCR5_maraviroc_2042_13114.shtml
September 20, 2007 -
Tim Horn -
Two-Year Vicriviroc Benefit in Treatment-Experienced Patients September 20, 2007 By Tim Horn Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in ... the cell's surface—either CCR5 or CXCR4. Vicriviroc, like Pfizer’s recently approved Selzentry (maraviroc), is ... make sure that all patients enrolled in the vicriviroc study had virus that was tropic for the ... phase of the study, the 5mg dose of vicriviroc was discontinued, due to poor efficacy. After ...
http://www.aidsmeds.com/articles/vicriviroc_CCR5_ACTG_2076_13070.shtml
September 20, 2007 -
Tim Horn -
September 20, 2007 Two-Year Vicriviroc Benefit in Treatment-Experienced Patients by Tim Horn Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in ... the cell's surface—either CCR5 or CXCR4. Vicriviroc, like Pfizer’s recently approved Selzentry (maraviroc), is ... make sure that all patients enrolled in the vicriviroc study had virus that was tropic for the ... phase of the study, the 5mg dose of vicriviroc was discontinued, due to poor efficacy. After ...
http://www.aidsmeds.com/articles/vicriviroc_CCR5_ACTG_1667_13070.shtml
July 31, 2007 -
... interpreted. Another drug, Schering-Plough's CCR5 inhibitor, vicriviroc. It s being presented here as well. I ... and the cancer alarm that went off? Well, vicriviroc, this is a much smaller study than MOTIVATE ... eight malignancies in the study six in the vicriviroc arm and two in the placebo arm. And ... really was no association with malignancies, so this vicriviroc thing I think we just need more information ... really in those duel mixed patients, maraviroc or vicriviroc just doesn t have activity, doesn t ...
http://www.aidsmeds.com/articles/experimental_aids_drugs_2021_12664.shtml
July 24, 2007 -
Tim Horn -
Vicriviroc Shows Benefits, Continues Development July 24, 2007 By ... reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in ... the study (A5211) was to see how well vicriviroc worked over 14 days in HIV-positive people ... Other goals were to study the safety of vicriviroc and to study the effects of vicriviroc on viral load and CD4 cell counts— ...
http://www.aidsmeds.com/articles/2021_12621.shtml
July 24, 2007 -
Tim Horn -
July 24, 2007 Vicriviroc Shows Benefits, Continues Development by Tim Horn The ... reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in ... the study (A5211) was to see how well vicriviroc worked over 14 days in HIV-positive people ... Other goals were to study the safety of vicriviroc and to study the effects of vicriviroc on viral load and CD4 cell counts— ...
http://www.aidsmeds.com/articles/1667_12621.shtml
April 24, 2007 -
Tim Horn -
... of other CCR5 inhibitors, notably Schering-Plough's vicriviroc and GlaxoSmithKline's aplaviroc. In one Phase II ... lymphoma – all of them among patients receiving vicriviroc – were reported in March 2006 by Schering-Plough. However, a causal relationship between the vicriviroc use and the lymphoma occurrences has not been ...
http://www.aidsmeds.com/articles/1667_11759.shtml
